Drug Type Small molecule drug |
Synonyms DEP® SN38, DEP® irinotecan, SN38 dendrimer nanoparticle |
Target |
Action inhibitors |
Mechanism TOP1 inhibitors(DNA topoisomerase I inhibitors) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
License Organization- |
Drug Highest PhasePhase 2 |
First Approval Date- |
Regulation- |
Molecular FormulaC22H20N2O5 |
InChIKeyFJHBVJOVLFPMQE-QFIPXVFZSA-N |
CAS Registry86639-52-3 |
| Indication | Highest Phase | Country/Location | Organization | Date |
|---|---|---|---|---|
| Advanced Malignant Solid Neoplasm | Phase 2 | Australia | 07 Aug 2019 | |
| Advanced Malignant Solid Neoplasm | Phase 2 | United Kingdom | 07 Aug 2019 | |
| Colorectal Cancer | Phase 2 | Australia | 07 Aug 2019 | |
| Colorectal Cancer | Phase 2 | United Kingdom | 07 Aug 2019 | |
| Platinum-Resistant Ovarian Carcinoma | Phase 2 | Australia | 07 Aug 2019 | |
| Platinum-Resistant Ovarian Carcinoma | Phase 2 | United Kingdom | 07 Aug 2019 | |
| Ovarian Cancer | Phase 2 | Australia | - |
Phase 1 | 114 | (Q3W) | wtectfzfar(smwvmijsoe) = Most DEP-SN38-attributed treatment-related adverse events (TRAEs) were mild/moderate (89.7%), with neutropenia the key dose-limiting toxicity and the most common grade 3/4 TRAE (48% of grade 3/4 events). Severe GI TRAEs were rare (grade 3 diarrhea and vomiting [0.9% of patients each]; nausea [1.8%]). Cholinergic symptoms were not observed. humzgjoris (vksgcoohor ) | Positive | 01 Aug 2025 | ||
(Q2W) | |||||||
Phase 1/2 | - | jgllyzqpxs(drvwobxfoo) = cbxlyxedqf hskdoksehv (wizrmqlvag ) | - | 15 Aug 2020 |





